Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature

Grisanti, Salvatore; Ferrari, Vittorio; Buglione, Michela; Agazzi, Giorgio Maria; Liserre, Roberto; Poliani, Pietro Luigi; Buttolo, Luciano; Gipponi, Stefano; Pedersini, Rebecca; Consoli, Francesca; Panciani, Pier Paolo; Roca, Elisa; Spena, Giannantonio; Triggiani, Luca; Berruti, Alfredo

doi:10.23736/s0390-5616.16.03874-1

Cited by 25 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF, a pro-angiogenic growth factor, is highly expressed in TAMs (Colegio et al, 2014;Qian and Pollard, 2010). Anti-VEGF therapy with bevacizumab (Cohen et al, 2009;Friedman et al, 2009;Lu-Emerson et al, 2015) or multiple RTK inhibitor sunitinib failed to improve survival J o u r n a l P r e -p r o o f in patients with recurrent glioblastoma multiforme (Grisanti et al, 2019). This is likely due to M2like macrophages, which promoted tumor angiogenesis and vascular abnormalization (Mazzieri et al, 2011;Qin et al, 2015;Rolny et al, 2011).…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance

Erin

Grahovac

Brozović

et al. 2020

Drug Resistance Updates

322

187

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance

Erin

Grahovac

Brozović

et al. 2020

Drug Resistance Updates

322

187

View full text Add to dashboard Cite

show abstract

“…Cabozantinib had good results both in vitro and in clinical trials, and PD173074 had good results in vitro [81,82]. Sunitinib is a multiple kinase inhibitor of VEGFR, PDGFR, FLT1, FLT1/KDR, FLT3, and RET kinases with no promising activity for GB patients [83].…”

Section: Receptor Tyrosine Kinase Inhibitors For Glioblastoma Treatmentmentioning

confidence: 99%

Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches

Alexandru¹,

Horescu²,

Sevastre³

et al. 2020

View full text Add to dashboard Cite

From all central nervous system tumors, gliomas are the most common. Nowadays, researchers are looking for more efficient treatments for these tumors, as well as ways for early diagnosis. Receptor tyrosine kinases (RTKs) are major targets for oncology and the development of small-molecule RTK inhibitors has been proven successful in cancer treatment. Mutations or aberrant activation of the RTKs and their intracellular signaling pathways are linked to several malignant diseases, including glioblastoma. The progress in the understanding of malignant glioma evolution has led to RTK targeted therapies with high capacity to improve the therapeutic response while reducing toxicity. In this review, we present the most important RTKs (i.e. EGFR, IGFR, PDGFR and VEGFR) currently used for developing cancer therapeutics together with the potential of RTK-related drugs in glioblastoma treatment. Also, we focus on some therapeutic agents that are currently at different stages of research or even in clinical phases and proved to be suitable as re-purposing candidates for glioblastoma treatment.

show abstract

“…This process could ultimately improve perfusion and drug delivery. In this context, promising results in reducing angiogenesis and normalizing vascularization have been shown by cediranib and sutinib (Batchelor et al, 2013;Grisanti et al, 2019).…”

Section: Small Molecules For Targeted Therapies In Gbmmentioning

confidence: 99%

The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices

Cintio

Baboci

et al. 2020

Front. Neurosci.

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most frequent and aggressive primary central nervous system tumor. Surgery followed by radiotherapy and chemotherapy with alkylating agents constitutes standard first-line treatment of GBM. Complete resection of the GBM tumors is generally not possible given its high invasive features. Although this combination therapy can prolong survival, the prognosis is still poor due to several factors including chemoresistance. In recent years, a comprehensive characterization of the GBM-associated molecular signature has been performed. This has allowed the possibility to introduce a more personalized therapeutic approach for GBM, in which novel targeted therapies, including those employing tyrosine kinase inhibitors (TKIs), could be employed. The GBM tumor microenvironment (TME) exerts a key role in GBM tumor progression, in particular by providing an immunosuppressive state with low numbers of tumor-infiltrating lymphocytes (TILs) and other immune effector cell types that contributes to tumor proliferation and growth. The use of immune checkpoint inhibitors (ICIs) has been successfully introduced in numerous advanced cancers as well as promising results have been shown for the use of these antibodies in untreated brain metastases from melanoma and from non-small cell lung carcinoma (NSCLC). Consequently, the use of PD-1/PD-L1 inhibitors has also been proposed in several clinical trials for the treatment of GBM. In the present review, we will outline the main GBM molecular and TME aspects providing also the grounds for novel targeted therapies and immunotherapies using ICIs for GBM.

show abstract

Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature

Cited by 25 publications

References 0 publications

Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance

Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance

Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches

The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices

Contact Info

Product

Resources

About